TUMOUR VACCINE

Ernst Wagner,; Ralf Kircheis,; Daan Crommelin; Maaike Van Slooten; Gert Storm,

TUMOUR VACCINE

Ernst Wagner, (Inventor), Ralf Kircheis, (Inventor), Daan Crommelin (Inventor), Maaike Van Slooten (Inventor), Gert Storm, (Inventor)

Biomaterials Science and Technology

Research output: Patent

Abstract

The invention relates to a tumour vaccine with a tumour antigen base. In addition to a source of tumour antigens, the vaccine contains a release system for the delayed release of the active agent IFN- gamma , the active dose of IFN- gamma being 50 ng to 5 mu g. The IFN- gamma is released over a period ranging from several hours to several days. The IFN- gamma release system consists preferably of liposomes, and the tumour antigen source preferably of allogenic tumour cells.

Original language	English
Patent number	WO9920301
IPC	A61P 35/ 00 A I
Priority date	18/10/97
Publication status	Published - 29 Apr 1999

Cite this

@misc{45d75592614c44e29b3246969d02af6a,

title = "TUMOUR VACCINE",

abstract = "The invention relates to a tumour vaccine with a tumour antigen base. In addition to a source of tumour antigens, the vaccine contains a release system for the delayed release of the active agent IFN- gamma , the active dose of IFN- gamma being 50 ng to 5 mu g. The IFN- gamma is released over a period ranging from several hours to several days. The IFN- gamma release system consists preferably of liposomes, and the tumour antigen source preferably of allogenic tumour cells.",

author = "Ernst Wagner, and Ralf Kircheis, and Daan Crommelin and {Van Slooten}, Maaike and Gert Storm,",

year = "1999",

month = apr,

day = "29",

language = "English",

type = "Patent",

note = "WO9920301; A61P 35/ 00 A I",

}

TY - PAT

T1 - TUMOUR VACCINE

AU - Wagner,, Ernst

AU - Kircheis,, Ralf

AU - Crommelin, Daan

AU - Van Slooten, Maaike

AU - Storm,, Gert

PY - 1999/4/29

Y1 - 1999/4/29

N2 - The invention relates to a tumour vaccine with a tumour antigen base. In addition to a source of tumour antigens, the vaccine contains a release system for the delayed release of the active agent IFN- gamma , the active dose of IFN- gamma being 50 ng to 5 mu g. The IFN- gamma is released over a period ranging from several hours to several days. The IFN- gamma release system consists preferably of liposomes, and the tumour antigen source preferably of allogenic tumour cells.

AB - The invention relates to a tumour vaccine with a tumour antigen base. In addition to a source of tumour antigens, the vaccine contains a release system for the delayed release of the active agent IFN- gamma , the active dose of IFN- gamma being 50 ng to 5 mu g. The IFN- gamma is released over a period ranging from several hours to several days. The IFN- gamma release system consists preferably of liposomes, and the tumour antigen source preferably of allogenic tumour cells.

M3 - Patent

M1 - WO9920301

ER -

TUMOUR VACCINE

Abstract

Fingerprint

Cite this